Rezlidhia™ (olutasidenib) – New orphan drug approval
December 1, 2022 - Rigel Pharmaceuticals announced the FDA approval of Rezlidhia (olutasidenib), for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
Top